Highlights from

AAN 2019

American Academy of Neurology annual meeting

Philadelphia, USA 4-10 May 2019

Atogepant effective and safe for migraine prevention

In a phase 2b/3 study, all 5 atogepant treatment arms showed statistically significant, clinically relevant reductions in mean migraine days compared to placebo [1]. Atogepant was well tolerated, with no treatment-related serious AEs.

Atogepant is a novel, oral calcitonin gene-related peptide receptor antagonist in development as a prophylactic treatment of episodic migraine. In this multicentre, randomised, double-blind, parallel-group trial, 795 adult patients with 4-14 migraine days (mean 7.67) in the 28-day baseline period were randomised 2:1:2:1:2:1 to placebo, atogepant 10 mg QD, 30 mg QD, 30 mg BID, 60 mg QD, or 60 mg BID, for 12 weeks. Mean change in monthly migraine days between atogepant treatment groups and placebo are listed in the Table. Adverse events were reported by 480 subjects; for 170, adverse events were considered treatment-related; 7 subjects reported serious adverse events but these were not treatment-related.

Table: Mean change in monthly migraine days with atogepant

Table Mean change in monthly migraine

QD, once daily; BID, twice daily

  1. Goadsby PJ, et al. AAN 2019, S17.001.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.